This funding augments the previously announced $15 million Series D financing.
AxioMed’s Freedom Lumbar Disc is currently on the market in the EU and advancing toward completion of its Investigational Device Exemption pivotal study in the U.S. AxioMed intends to follow a similar regulatory and marketing pathway as the FLD with its Freedom Cervical Disc, which recently received a CE Mark for introduction in the EU.
Related Articles on Spine Devices:
20 Spine Devices Receive FDA 510(k) Clearance in May
Korean FDA Approves Mazor Robotics’ Renaissance Robotic Platform
Crocker Spinal Technologies to Develop BYU Spine Device
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.